Premium
Effects of Ketanserin, a 5‐HT 2 ‐Receptor Antagonist, on the Blood Flow Response to Temperature Changes in the Diabetic Foot
Author(s) -
Schneider S. H.,
Tendler M.,
Apelian A.,
Jageneau A. H. M.,
Khachadurian A. K.
Publication year - 1985
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1985.tb02868.x
Subject(s) - ketanserin , saline , bolus (digestion) , medicine , anesthesia , blood flow , reactive hyperemia , endocrinology , serotonin , hemodynamics , plethysmograph , 5 ht receptor , receptor
We studied the effect of ketanserin, a relatively specific antagonist for 5‐hydroxytryptamine 2 ‐serotonergic receptors, on the total blood flow to the foot of patients with diabetes using a computerized pulse volume Plethysmograph and a temperature controlled foot chamber. Ketanserin was administered intravenously as a bolus of 10 mg over four minutes followed by a constant infusion at the rate of 5 mg/hr. Saline infusion served as a control in each subject. Sixteen patients with type II diabetes and two patients with type I diabetes were studied. Mean age was 58.5 ± 1.6 years and mean duration of diabetes was 10 ± 2 years. Basal blood flow (mean ± SEM, mL/100 mL/min) at room temperature was 3.77 ± 0.99 with saline and 12.07 ± 1.81 with ketanserin. At 38 to 40°C, the values were 4.84 ± 1.09 and 16.93 ± 1.83. Reactive hyperemia was measured following three minutes of arterial occlusion; at 38 to 40°C the flow rate was 20.67 ± 2.45 with saline and 30.86 ± 3.02 with ketanserin, while at 8 to 10°C the corresponding values were 15.63 ± 2.01 and 27.16 ± 2.03. All differences between saline and ketanserin had a P < .01. Venous distensibility (vol% at 50 mm Hg) at 8 to 10°C was 0.55 ± 0.05 with saline and 0.90 ± 0.15 with ketanserin , P < .05. Our findings are consistent with the hypothesis that serotonin is involved in the limitation of blood flow to the foot in diabetes and that ketanserin may play a potential role in therapy .